Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain
Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer ( Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
13 Jul 2026

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

Dr Kozo Kataoka - Hyogo Medical University, Nishinomiya, Japan
ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas ( Dr Kozo Kataoka - Hyogo Medical University, Nishinomiya, Japan )
6 Jul 2026

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer ( Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
10 Jun 2026

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2026

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer

Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain
Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer ( Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain )
1 Jun 2026

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan
Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )
1 Jun 2026

Structured exercise programme improves survival and reduces healthcare costs in colon cancer

Dr Kelvin K. Chan - Sunnybrook Odette Cancer Centre, Toronto, Canada
Structured exercise programme improves survival and reduces healthcare costs in colon cancer ( Dr Kelvin K. Chan - Sunnybrook Odette Cancer Centre, Toronto, Canada )
1 Jun 2026

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Dr Jessica Paulus - Ontada, Boston, USA
Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps ( Dr Jessica Paulus - Ontada, Boston, USA )
1 Jun 2026

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )
31 May 2026

Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma

Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China
Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma ( Dr Xue-Feng Leng - Sichuan Cancer Hospital & Institute, Chengdu, China )
30 May 2026

Bezuclastinib sunitinib combo shows promise in second-line GIST treatment

Dr Andrew J. Wagner - Dana-Farber Cancer Institute, Boston, USA
Bezuclastinib sunitinib combo shows promise in second-line GIST treatment ( Dr Andrew J. Wagner - Dana-Farber Cancer Institute, Boston, USA )
30 May 2026